Postprandial hyperglycemia and diabetic complications;Iperglicemia post-prandiale e complicanze diabetiche

Recenti Progressi in Medicina

Volumn 96, Issue 9, 2005, Pages 436-444

  Da Ros, Roberto ^a   Assaloni, Roberta ^a   Ceriello, Antonio ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b Dipartimento di Medicina Interna   (Italy)

Author keywords

Cardiovascular disease; Diabetic complications; Impaired glucose tolerance; Oxidative stress; Postprandial hyperglycemia

Indexed keywords

FREE RADICAL; GLUCOSE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE MODEL; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 25144450032     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Kannel WB, McGee DL. Diabetes and cardiovascular diseases: the Framingham Study. JAMA 1979; 241: 2035-8.
2. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
3. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107-14.
4. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000: 405-12.
5. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
7. Vinik AI, Jenkins DJ. Dietary fiber in management of diabetes. Diabetes Care 1988; 11: 160-73.
8. Wolever TMS, Chiasson JL, Csima A, Hunt JA, Palmason G, Ross SA, Ryan EA. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998; 21: 336-40.
9. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels GBLM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-31.
10. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987; 36: 689-92.
11. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care 1997; 20: 163-9.
12. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.
13. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-40.
14. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-7.
15. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. the DIS Group: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83.
16. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144: 229-35.
17. Temelkova-Kurktschiev TS, Koehler C, Schaper F, Leonhardt W, Henkel H, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose and HbA1c level. Diabetes Care 2000; 23: 1830-4.
18. Bellodi G, Manicardi V, Malavasi V, Veneri L, Bernini G, Bossini P, et al. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1989; 64: 885-8.
19. O' Sullivan JJ, Conroy RM, Robinson K, Hickey N, Mulcahy R. In hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care 1991; 14: 758-60.
20. Gray CS, Taylor R, French JM, Alberti KG, Venables GS, James OF, et al. The prognostic value of stress hyperglycaemia and previosly unrecognized diabetes in acute stroke. Diabet Med 1987; 4: 237-40.
21. Gray CS, French JM, Bates D, Cartlidge NE, Venables GS, James OF. Increasing age, diabetes mellitus and recovery from stroke. Postgrad Med J 1989; 65: 720-42.
22. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-8.
23. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation 1999; 99: 2626-32.
24. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000; 43: 571-5.
25. Gokhroo R, Mittal SR. Electrocardiographic correlates of hyperglycemia in acute myocardial infarction. Int J Cardiol 1989; 22: 267-9.
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
27. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.
28. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-8.
29. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6.
30. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 29: 2978-84.
31. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010-4.
32. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996; 45: 762-7.
33. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR. Postprandial low density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999; 222: 178-84.
34. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, et al. Meal-induced oxidative stress and lowdensity lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999; 48: 1503-8.
35. Jorgensen RG, Russo L, Mattioli L, Moore WV: Early detection of vascular dysfunction in type I diabetes. Diabetes 37: 292-296, 1988
36. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, et al. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167-E73.
37. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-54.
38. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-90.
39. Shige H, Ishikawa T, Suzukawa M, Ito T, Nakajima K, Higashi K, et al. Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 1999; 84: 1272-4.
40. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-25.
41. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest 1979; 63: 485-93.
42. Jones RL. Fibrinopeptide A in diabetes mellitus: relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 1985; 34: 836-41.
43. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 1989; 38: 1162-3.
44. Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, et al. Hyperglycemia-induced thrombin formation in diabetes: the possible role of the oxidative stress. Diabetes 1995; 44: 924-8.
45. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-91.
46. Sakamoto T, Ogawa H, Kawano H, Hirai N, Miyamoto S, Takazoe K, et al. Rapid change of platelet aggregability in acute hyperglycemia: detection by a novel laser-light scattering method. Thromb Haemost 2000; 83: 475-9.
47. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel G, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-73.
48. Ruosladti E. Integrins. J Clin Invest 1991; 187: 1-5.
49. Lopes-Virella MF, Virella G. Immune mechanism of atherosclerosis in diabetes mellitus (Review). Diabetes 1992; 41 (Suppl. 2): 86-91.
50. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemostas 1994; 72: 151-4.
51. Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995; 38: 1122-24.
52. Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, et al. Increased circulating ICAM-1 levels in type-2 diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism 1996; 45: 498-501.
53. Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998; 30: 146-9.
54. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000; 101: 2247-51.
55. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord 2004; 5: 255-9.
56. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-72.
57. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002; 39: 1145-50.
58. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
59. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003; 26: 1589-96.
60. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: a effect prevented by vitamin C and E. J Am Coll Cardiol 2000; 36: 2185-91.
61. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001; 103: 1618-23.
62. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, et al. Antioxidant defenses are reduced during oral glucose tolerance test in normal and non-insulin dependent diabetic subjects. Eur J Clin Invest 1998; 28: 329-33.
63. Tessier D, Khalil A, Fulop T. Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. J Gerontol 1999; 54: 541-5.
64. Konukoglu D, Hatemi H, Ozer EM, Gonen S, Akcay T. The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Invest 1997; 20: 471-5.
65. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998; 21: 1529-33.
66. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171-5.
67. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439-43.
68. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-C1437.
69. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003; 289: 1675-80.
70. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001; 107: 853-60.
71. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects (Letter). J Clin Invest 2001; 108: 635-6.
72. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-8.
73. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004; 53: 701-10.
74. Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Marfella R, Nappo F, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002; 51: 1076-82.
75. Mihm MJ, Jing L, Bauer JA. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol 2000; 36: 182-87.
76. Taskinen MR, Lahdenpera S, Syvanne M. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 335-40.
77. Karpe F, de Faire U, Mercuri M, Bond MG, Hellenius ML, Hamsten A. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis 1998; 141: 307-14.
78. Cavallero E, Dachet C, Neufcou D, Wirquin E, Mathe D, Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 1994; 43: 270-8.
79. Heine RJ, Dekker JM. Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45: 461-75.
80. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-23.
81. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol 2000; 11: 9-23, 2000.
82. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-83.
83. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-6.
84. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract 1999; 46: 23-7.
85. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-5.
86. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-8.
87. Bastyr EJ 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c: IOEZ Study Group. Diabetes Care 2000; 23: 1236-41.
88. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients: U.K. Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-9.
89. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21-B29.
90. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-73.
91. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Org 1999.
92. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 2004; 27 (Suppl. 1): S15-S35.
93. American College of Endocrinology. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002; 8: 5-11.
94. Alberti KGMM, Gries FA: Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabet Med 1988; 5: 275-81.
95. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27 (Suppl. 2): 1-163.
96. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. and the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
97. American Diabetes Association. Postprandial blood glucose (Review). Diabetes Care 2001; 24: 775.